Syamala Volga S, Syamala Vani, Sheeja V R, Kuttan Ratheesan, Balakrishnan Rajan, Ankathil Ravindran
Regional Cancer Centre, Division of Cancer Research, Medical College Post, Thiruvananthapuram, India.
Cancer Invest. 2010 Mar;28(3):304-11. doi: 10.3109/07357900902744494.
This case control study investigated whether polymorphisms of estrogen metabolizing genes CYP1A1 MspI, CYP17 MspAI, COMT Val(158) Met, and SULT1A1 Arg(213) His have any role in familial breast cancer susceptibility risk. Logistic regression analysis adjusted to age was used to calculate odds ratios (ORs) and 95% confidence intervals (95%CIs). Familial breast cancer risk due to CYP1A1 wt/m1 and m1/m1 genotypes was 2.3 (1.51-3.61)-fold and 7.1 (3.69-13.7)-fold, respectively. In addition to the main effects, certain first-order interactions were also significantly associated with familial breast cancer. Our results favor a possible risk modification by estrogen metabolizing gene polymorphisms in familial breast cancer susceptibility.
这项病例对照研究调查了雌激素代谢基因CYP1A1 MspI、CYP17 MspAI、儿茶酚-O-甲基转移酶Val(158)Met和磺基转移酶1A1 Arg(213)His的多态性在家族性乳腺癌易感性风险中是否起作用。采用调整年龄后的逻辑回归分析来计算比值比(OR)和95%置信区间(95%CI)。CYP1A1 wt/m1和m1/m1基因型导致的家族性乳腺癌风险分别为2.3(1.51 - 3.61)倍和7.1(3.69 - 13.7)倍。除主要效应外,某些一阶相互作用也与家族性乳腺癌显著相关。我们的结果支持雌激素代谢基因多态性可能对家族性乳腺癌易感性产生风险修饰作用。